A drug delivery device is provided. In an embodiment, the device includes a device body having an elongated drug reservoir lumen, a drug positioned in the drug reservoir lumen, and at least one end plug positioned at an end of the device body, for example inserted in an end of the drug reservoir lumen. The end plug may include an aperture therethough, and the drug delivery device may be configured to release the drug from the drug reservoir lumen through the aperture.

Provided herein, inter alia, are methods and compositions for inhibiting v1 integrin and for treating fibrosis.

Provided herein, inter alia, are methods and compositions for inhibiting v1 integrin and for treating fibrosis.

The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

An oto-block applicator, includes a plunger, an oto-block holder configured to couple to the plunger; and an insertion stop coupled to said oto-block holder, wherein the insertion stop is configured to prevent insertion of the oto-block holder past a predetermined distance into the ear, and the plunger is configured to push an oto-block held within the oto-block holder out of a front end of the oto-block holder and into the user's ear.

The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

The present invention is a vaginal device platform comprising an insertable therapeutic delivery device for delivering one or more therapeutic agents, comprising any of pharmaceutical, medicinal, or holistic components, directly to the mucosa of the vaginal canal and a means of recovering the device. The delivery device platform may be used to dispense one or more therapeutic agents. In one embodiment, a static insert device is used, in another embodiment the insert device is used in an applicator to deliver a dosage amount from the applicator along with the insertion of the insert device.

The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

A medical device, for example a delivery catheter, may include a handle portion, a shaft portion extending distally from the handle portion, a deployment mechanism, and an actuation member positioned on the handle portion. The shaft portion may include a working channel and a distal tip portion having a payload chamber configured to receive a payload, such as a bio-absorbable foam. The distal tip portion may be operatively connected to the working channel. The deployment mechanism may be positioned in the working channel, and may be operable to deploy the payload out from the distal tip portion. The actuation member may be actuatable to operate the deployment mechanism.

An implantable leadless pacing device and delivery system may comprise an implantable leadless pacing device and a catheter configured to deliver the implantable leadless packing device to a target location. The implantable device may comprise a power source, circuitry operatively coupled to the power source, a housing at least partially enclosing the circuitry, a first electrode secured relative to and offset from a longitudinal axis of the housing and exposed exterior to the housing, and a fixation mechanism secured relative to the housing. The fixation mechanism may comprise at least one tine configured to move between an elongated delivery configuration and a curved deployed configuration and radially offset from the first electrode. The catheter may comprise a distal holding section defining a cavity configured to receive the implantable leadless pacing device.